{
    "2018-08-01": [
        [
            {
                "time": "",
                "original_text": "董秘解码：国脉科技正式从事临床细胞分子遗传医学检验服务",
                "features": {
                    "keywords": [
                        "国脉科技",
                        "临床",
                        "细胞分子",
                        "遗传医学",
                        "检验服务"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[增持评级] 昭衍新药(603127)简评：业绩维持高速增长 订单及产能带动增量",
                "features": {
                    "keywords": [
                        "昭衍新药",
                        "增持评级",
                        "业绩",
                        "高速增长",
                        "订单",
                        "产能"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "研发服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}